Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. reports news on its dermatology therapeutics business, including commercialization of YCANTH (VP-102) for molluscum contagiosum and development of cantharidin-based therapy for common warts. Company updates also cover financial results, corporate presentations, commercial leadership and international commercialization activity.
Verrica’s pipeline news centers on VP-315 (ruxotemitide), an oncolytic peptide licensed for dermatologic oncology indications. Recurring disclosures include clinical data presentations in basal cell carcinoma, development plans for non-melanoma skin cancers and collaboration activity tied to YCANTH and its dermatology portfolio.
Verrica Pharmaceuticals (Nasdaq: VRCA) will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss second quarter 2026 financial results and provide a corporate update. Participants can join via domestic dial-in 1-800-225-9448, international 1-203-518-9708, using conference ID: VERRICA, or through the investor relations section of the company website.
A replay of the webcast will be archived on Verrica’s website for 90 days. Verrica develops and commercializes treatments for dermatological diseases, including FDA-approved YCANTH (VP-102) for molluscum contagiosum, and is developing YCANTH for common warts and VP-315 under license from Lytix Biopharma for non-melanoma skin cancers.
Verrica Pharmaceuticals (Nasdaq: VRCA) has entered into an exclusive distribution, marketing and supply agreement with Medomie Pharma, granting Medomie rights to seek regulatory approval for and distribute YCANTH for molluscum contagiosum in Israel. Verrica will manufacture YCANTH, supply commercial product to Medomie, and receive 60% of the net selling price of YCANTH sold in Israel, plus eligibility for up to $8.2 million in regulatory and commercial milestone payments.
YCANTH, a proprietary cantharidin-based, single-use applicator treatment, is the first and only FDA-approved, healthcare professional-administered therapy for molluscum in patients aged two years and older, supported by Phase 3 trials in about 500 patients and broad U.S. insurance coverage.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported dosing the first U.S. patient in COVE-3, the second pivotal Phase 3 trial of YCANTH (VP-102) for common warts. Torii Pharmaceutical recently dosed the first Japanese patient. A prior Phase 2 trial showed 51% complete clearance at Day 84. Torii will fund the first $40 million of Phase 3 costs, about 90% of the current budget, under a 50/50 cost-sharing agreement.
Verrica Pharmaceuticals (NASDAQ: VRCA) announced that President and CEO Jayson Rieger will present at the Jefferies Global Healthcare Conference in New York.
The presentation is scheduled for Thursday, June 4, 2026, at 11:05 a.m. ET, with a live and replay webcast available via Verrica’s investor website.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Jayson Rieger, PhD, MBA, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, at 1:30 p.m. ET.
A live webcast and 90-day replay will be available via Verrica’s investor relations website.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported Q1 2026 revenue of $5.0 million, including U.S. YCANTH net product revenue of $4.3 million, up 16.2% sequentially and 25.4% year-over-year. Dispensed YCANTH applicator units reached 15,302, up 12.1% sequentially and 51.3% year-over-year.
YCANTH surpassed 100,000 total dispensed units since launch and was commercially launched in Japan by partner Torii. Verrica reported a GAAP net loss of $9.7 million and continues Phase 3 programs in common warts and development of VP-315 for basal cell carcinoma.
Verrica Pharmaceuticals (Nasdaq: VRCA) will present Phase 2 data on VP-315 (ruxotemitide) showing reductions in untreated basal cell carcinoma (BCC) lesions consistent with a potential abscopal effect. In 9 subjects, 14 non-treated lesions showed a 67% overall size reduction and 21% complete histologic clearance (3/14).
The poster will be presented May 15, 2026 at the SID Annual Meeting and reports an average 86% overall tumor-size reduction referenced for treated patients.
Verrica Pharmaceuticals (Nasdaq: VRCA) will report first-quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026 at 4:30 p.m. ET.
The company will host a conference call and live webcast; domestic and international dial-in numbers and a conference ID (VERRICA) are provided. A webcast replay will be archived on Verrica's investor website for 90 days.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced acceptance of a late-breaking abstract reporting Phase 2 exploratory data for VP-315, its oncolytic peptide for basal cell carcinoma, showing a potential abscopal effect in untreated non-target BCC tumors.
The data will be presented at the 2026 Society for Investigative Dermatology Annual Meeting, May 13-16, with the poster session on May 15, 2026 (4:30 pm–6:00 pm) in Chicago (Hilton Chicago, Salons B,C,D).
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Jayson Rieger, PhD, MBA, will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:00pm ET.
A live webcast will be available via Verrica's investor site and a replay will be posted and available for 90 days.